CCX 507

Drug Profile

CCX 507

Alternative Names: CCX-507; CCX507 B

Latest Information Update: 24 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemoCentryx
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action CCR9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammatory bowel diseases; Ulcerative colitis

Highest Development Phases

  • Phase I Inflammatory bowel diseases

Most Recent Events

  • 24 Nov 2016 Phase-I development is ongoing in USA and Netherlands
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Inflammatory-bowel-disease(In volunteers) in USA (PO)
  • 21 Oct 2014 Pharmacodynamics & adverse events data from a phase I trial in Healthy volunteers presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology (ACG-2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top